Efficacy and safety of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism inadequately controlled with cinacalcet

Efficacy and safety of etelcalcetide in hemodialysis patients with secondary hyperparathyroidism inadequately controlled with cinacalcet - SWITCH Study

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030568

Enrollment

Registered

2017-12-27

Start date

2017-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary hyperparathyroidism

Interventions

Etelcalcetide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Intact PTH >=300 pg/ml Receiving cinacalcet

Exclusion criteria

Exclusion criteria: Corrected serum calcium <8.4 mg/dL Receiving hemodialysis less than three months

Design outcomes

Primary

Measure	Time frame
Proportion of patients with mean intact PTH levels during weeks 20-24 of 60-240 pg/ml.	—

Secondary

Measure	Time frame
Proportion of patients with >=30% reduction from baseline in mean intact PTH levels during weeks 20-24; changes from baseline in serum calcium, phosphorus, intact PTH, alkaline phosphatase, magnesium, and calcitonin; and adverse events	—

Countries

Japan

Contacts

Public ContactHiroo Takahashi

Jinken Clinic Not applicable

htp911@cocoa.ocn.ne.jp046-231-8151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026